CVM’s Procedure for Setting Tolerances

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Effectiveness Evaluation for Production Drugs Crystal Groesbeck, Ph.D Division of Production Drugs.
CODE OF PRACTICE AND COMMODITIES STANDARDS, PRESENTED AT NIGERIA AFLATOXIN WORKSHOP BY STANDARDS ORGANISATION OF NIGERIA.
TRP Chapter Chapter 2.3 Environmental impacts and health risks.
Use of pesticides and residues in wine Patrizia Restani SCRAISIN - March 2009 Patrizia Restani SCRAISIN - March 2009.
CONFERENCE ON “ FOOD ADDITIVES : SAFETY IN USE AND CONSUMER CONCERNS“ JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY NAIROBI, 24 JUNE 2014.
1 Pharmacology/Toxicology information to submit an IND for an anticancer drug.
6/14/2012FDA/CVM 1 Tong Zhou, Ph.D., DABT Division of Human Food Safety Office of New Animal Drug Evaluation Center for Veterinary Medicine US Food and.
Exposure Assessment Thanks to Marc Rigas, PhD for an earlier version of this lecture Much of the materials is drawn from Paustenbach, DJ. (2000) The practice.
Key issues in biopesticide regulation Pesticides Safety Directorate 19 June 2007.
What Do Toxicologists Do?
Risk Assessment II Dec 9, Is there a “safe” dose ? For effects other than cancer:
Stefan Franzén Introduction to clinical trials.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
U of Arizona Innovation Conference 20 September 2011 Marlene E. Haffner, MD, MPH Haffner Associates, LLC.
Food Safety Assessment Kevin Greenlees, PhD, DABT Kathleen Jones, PhD.
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
FDA’s Policy for Evaluating Bioengineered Foods Jeanette Glover Glew Food and Drug Administration Center For Food Safety and Applied Nutrition September,
Why Risk Analysis?  General public concern over real or imaged food- borne hazards to health  Recognition of the absence of systematic framework for.
DSHEA and Bioavailability Elizabeth A. Yetley, Ph.D. Ctr. Food Safety & Applied Nutrition Food and Drug Administration.
Animal Feed GRAS Notifications Geoffrey K. Wong, M.S. Division of Animal Feeds Center for Veterinary Medicine Pet Food Institute Pet Food Institute October.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
Stages of drug development
Guidance for Industry M4S: The CTD-Safety
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Training Session Product File Notes and Registration Reports, 23 October Product File Note Part Residues Frédéric Joris and Bruno Dujardin Federal.
Stefan Franzén Introduction to clinical trials.
When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.
SMMSS - Support to Modernisation of Mongolia Standardisation System Food Chain Risk Assessment and Management - Seminar on Food Safety Ulaanbaatar / Mongolia.
Approaches for Evaluating the Relevance of Multiroute Exposures in Establishing Guideline Values for Drinking Water Contaminants Kannan Krishnan, Université.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Anthelmintic discovery and registration Nick Sangster Faculty of Veterinary Science University of Sydney.
Exploratory IND Studies
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Copyright © 2002 University of Maryland School of Nursing. All rights reserved. Comparison of Pharmacology and Toxicology This material was developed at.
Risk Assessment Nov 7, 2008 Timbrell 3 rd Edn pp Casarett & Doull 7 th Edn Chapter 7 (pp )
RISK ASSESSMENT. Major Issues to be considered in designing the Study 1.- Emission Inventory What is the relative significance of the various sources.
Module 3 Risk Analysis and its Components. Risk Analysis ● WTO SPS agreement puts emphasis on sound science ● Risk analysis = integrated mechanism to.
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.
FAO/WHO Codex Training Package Module 4.3 FAO/WHO CODEX TRAINING PACKAGE SECTION FOUR – SCIENTIFIC BASIS FOR CODEX WORK 4.3 What is JECFA?
Nutraceuticals & New Dietary Ingredients The Swiss Perspective Willi Hunziker, DVM, MBA
Codex Science-based Approach to the Safety of Foods Derived from Modern Biotechnology James H. Maryanski, Ph.D. Food and Drug Administration Center for.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.
C LINICAL R ESEARCH. CONTENTS Drug Development Process Pre – Clinical Studies Clinical Trials Phase I Phase II Phase III Phase IV 2.
Using Product Development Information to Address the Bioequivalence Challenges of Highly-variable Drugs Lawrence X. Yu, Ph. D. Director for Science Office.
Session VII WEIGHING IN ON MICROBIOLOGICAL ADI: EXPERIENCES AND PERSPECTIVES Introduction October 26, 2012.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
The Future of Chemical Toxicity Testing in the U.S.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM Labeling Issues.
Substance Structure, production process and indented use Is there adequate published safety data and exposure data for this substance to meet current GRAS.
FOOD AND NUTRITIONAL TOXICOLOGY
Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern Qualitative Antimicrobial.
DERIVATION OF FOOD SAFETY STANDARDS Lecture Material - Food Safety Budi Widianarko - UNIKA SOEGIJAPRANATA.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
1. Consumers, Health, Agriculture and Food Executive Agency Risk assessment with regard to food and feed safety Risk analysis Why risk assessment in the.
Regulation of Generic Animal Drugs in the United States
Regulatory Approval Process for Veterinary Drugs – A Global Perspective M. R. Srinivasan and P. Sriram Laboratory Animal Medicine, Centre for Animal Health.
Regulation for Aquaculture Medicine Dr. Sasi Jaroenpioj Department of Livestock Medicine THAILAND 8 July 2015.
Overview of FDA’s Program for Reviewing New Food Contact Substances
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
Risk Assessment Dec 4 -6, 2006.
Introduction to Risk Assessment
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

CVM’s Procedure for Setting Tolerances Lynn G. Friedlander, Ph. D. Division of Human Food Safety Residue Chemistry Team

Tolerance Setting Chemical residues Other approaches

Tolerance Setting Residue: Any compound present in the edible tissues of the target animal which results from the use of the sponsored compound, including the sponsored compound, its metabolites, and any other substances formed in or on food because of the sponsored compound’s use. 21 CFR 500.82 (b)

Tolerance Setting Office of New Animal Drug Evaluation Division of Human Food Safety Toxicity data from the model species Microbial safety data Residue data from the target food-producing species Analytical methodology Good Laboratory Practices (GLP)

Tolerance Setting-Toxicology Basic Toxicology Package Additional/special toxicology studies Calculate the No Observable Effect Level (NOEL) Determine the appropriate safety factor Calculate the Allowable Daily Intake (ADI)

Tolerance Setting-Toxicology ADI = No Observable Effect Level Safety Factor

Tolerance Setting-Toxicology Calculating the Safe Concentration Safe Concentration = ADI x 60 kg consumption factor

Tolerance Setting-Toxicology The safe concentration is the amount of residue that can be eaten in any edible tissue each day for an entire lifetime without exposing the consumer to residues in excess of the ADI.

Tolerance Setting-Residue Chemistry Risk = Hazard X Exposure Mitigates the hazard identified in the toxicology safety studies by controlling exposure to the hazard through the assigning of tolerances and withdrawal periods or milk discard periods, where needed.

Tolerance Setting-Residue Chemistry Basic Studies Comparative Metabolism-Toxicology Species Total Residue and Metabolism-Target Species Analytical Method Residue Depletion/Withdrawal-Target Species

Tolerance Setting-Residue Chemistry Comparative Metabolism Study Did the toxicology testing evaluate the right compound(s)? Qualitative comparison of the metabolic profiles in the toxicological and food-producing species Ensures that the toxicological species has been exposed to the same residues to which humans will be exposed when they consume products derived from treated food-producing animals If profiles are not comparable, more toxicology testing may be indicated.

Tolerance Setting-Residue Chemistry Total Residue and Metabolism Study Radiolabeled drug 1-1.5X the proposed dose Proposed route of administration Intended duration of treatment/steady state Intended species; males and females

Tolerance Setting-Residue Chemistry Total Residue and Metabolism Study Determines the MARKER RESIDUE the residue that monitors the depletion of total residues in a tissue Determines the TARGET TISSUE generally, the edible tissue from which residues deplete most slowly often, liver or kidney rarely, muscle or fat

Tolerance Setting-Residue Chemistry Total Residue and Metabolism Study Provides a METABOLISM PROFILE in the food-producing animal for comparison with the metabolism profile of the toxicological species Establishes the MARKER:TOTAL ratio to calculate the tolerance

Tolerance Setting-Residue Chemistry Analytical Methodology Determinative measures concentrations of drug residues in tissue Confirmatory verifies the identity of the drug residue Screening assesses impact the new drug on pre-existing residue tests not required

Time (days) Drug Concentration 0.01 0.1 1000.0 100.0 10.0 1.0 1 2 3 4 Total Residue Marker Residue Safe Concentration 5

Tolerance Setting-Residue Chemistry Determine the time at which the concentration of total radiolabeled residues in the target tissue is less than the target tissue safe concentration Determine the concentration of the marker residue in the target tissue at that time using the proposed analytical methodology

Tolerance Setting-Residue Chemistry The concentration of the marker residue in the target tissue at the time the total radiolabeled residue in the target tissue has depleted to less than the target tissue safe concentration is the target tissue TOLERANCE

Tolerance Setting-Residue Chemistry Can establish tolerances for more than one tissue, i.e., target tissue and muscle must have data for the tissue(s) to support the tolerance assignment(s) often these data are available as part of the total residue and metabolism study

Time (days) Drug Concentration 0.01 0.1 1000.0 100.0 10.0 1.0 1 2 3 4 Total Residue Tolerance Marker Residue Safe Concentration 5

Tolerance Setting-Residue Chemistry Target tissue tolerance is a monitor for the depletion of residues from all the edible tissues When the concentration of the marker residue in the target tissue is less than the target tissue tolerance, total residues in all of the edible tissues are less than their respective safe concentrations

Tolerance Setting-Residue Chemistry Non-target tissue tolerance monitors depletion of residues only from the specific non-target tissue For example, if we assign a muscle tolerance and muscle is not the target tissue: Muscle tolerance monitors the depletion of residues from the muscle When the concentration of the marker residue in the muscle is less than the muscle tolerance, the total residues in the muscle are less than the muscle safe concentrations Muscle tolerance does not monitor any other edible tissues

Tolerance Setting-Residue Chemistry links the ADI and safe concentrations of total radiolabeled residues to “cold” residues that result from the use of the proposed market formulation as measured with the regulatory analytical method

Tolerance Setting-Residue Chemistry

Tolerance Setting-Residue Chemistry Applying the Tolerance The preslaughter withdrawal period and, if applicable, the milk discard period on the product labeling in the relevant section of 21 CFR Part 500 The established tolerance is codified under 21 CFR 556

Tolerance Setting-Residue Chemistry Applying the Tolerance US Approvals